Document is current
Any future updates will be listed below
-
Authors
Donhauser, Theresa https://orcid.org/0000-0002-0640-1169
Apfelbacher, Christian
Kann, Gesina
Masur, Clarissa
Kamudoni, Paul
Salek, Sam
Abels, Christoph
Gabes, Michaela
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03658616 at ClinicalTrials.govDocuments that mention this clinical trial
Hyperhidrosis quality of life index (HidroQoL): further validation by applying classical test theory and item response theory using data from a phase III clinical trial
https://doi.org/10.1186/s41687-023-00596-6
-
Funding
Funding for this research was provided by:
Dr. August Wolff GmbH & Co. KG Arzneimittel
Otto-von-Guericke-Universität Magdeburg
- License Information
-
More Information
Article History
Received: 16 December 2022
Accepted: 23 May 2023
First Online: 6 June 2023
Declarations
:
: Ethical approval was obtained by the corresponding ethics committees of the different countries.
: Not applicable.
: Christian Apfelbacher has received institutional funding from Dr. August Wolff GmbH & Co. KG Arzneimittel, and consultancy fees from Dr. August Wolff GmbH & Co. KG Arzneimittel, LEO Pharma, RHEACELL and Sanofi Genzyme. Clarissa Masur is and Christoph Abels was an employee of Dr. August Wolff GmbH & Co. KG Arzneimittel. Paul Kamudoni is a developer of the HidroQoL and is an employee of Merck Healthcare KgaA. Sam Salek is a joint developer of the HidroQoL, has received unrestricted educational grants from GlaxoSmithKline, European Hematology Association, Novartis, Bristol Meyer Squib, Sanofi, Celgene and consultancy fees from Pfizer and Agios.
